Ethex recalls three lots of dextroamphetamine tablets
This article was originally published in Scrip
KV Pharmaceutical's Ethex generics division has recalled three lots of dextroamphetamine 5mg tablets owing to the possible presence of oversized tablets which may contain twice the labelled amount of active ingredient. The recalled lots were distributed under the Ethex label between January 2007 and May 2008. The company said it found a small number of oversized tablets in lots that had not yet been distributed. There have been no reports from wholesalers, retailers or consumers about oversized tablets and no reports of unexpected side effects or injuries.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
Office of New Drugs Director Peter Stein tells the Pink Sheet that last phase of massive reorg was complicated by pandemic restrictions that forced review staff to work remotely, but the structural overhaul resulted in smaller, more nimble review groups and the breaking down of silos that ultimately helped the agency’s response to the public health crisis.
Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.